Ipca slumps after US import alert, ripple effect fears
This article was originally published in Scrip
Shares of Ipca Laboratories fell sharply following news of an FDA import alert against the company's active pharmaceutical ingredients (APls) unit in Ratlam and concerns on whether other international regulators may follow suit.
You may also be interested in...
India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.
Astellas’s senior director, head of enterprise insights and digital solutions, digital, analytics and technology tells Scrip how data analytics and deductive hypothesis-oriented simulation are driving improved strategic decision-making across the organization. He also outlined some early generative AI use cases and the promise of digital twins in medicine.
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.